New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:08 EDTIMMUImmunomedics announces presentation of epratuzumab data
Immunomedics announced that scientific data on epratuzumab, an investigational therapy for the treatment of systemic lupus erythematosus, also known as lupus, will be presented at the European League Against Rheumatism 2014 Annual Congress to be held in Paris, France. Epratuzumab is an investigational medicine in Phase III clinical development for the treatment of SLE. Epratuzumab is a monoclonal antibody that targets CD22. Epratuzumab is not approved for the treatment of SLE by any regulatory authority worldwide. Immunomedics has granted UCB exclusive worldwide rights to develop, market, and sell epratuzumab for all autoimmune disease indications.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
08:46 EDTIMMUImmunomedics reports Phase 1/2 results with sacituzumab govitecan
Immunomedics announced that sacituzumab govitecan, the company's lead investigational antibody-drug conjugate, or ADC, produces partial response, or PR, in some patients with metastatic esophageal and colorectal cancers who had been heavily pretreated. Extended periods of stable disease were also noted in some patients with pancreatic and gastric cancers, with time-to-progression, or TTP, exceeding that of last prior therapy in many cases. Response and TTP were evaluated by computed tomography, or CT, based on RECIST criteria. Patented and developed by the company, sacituzumab govitecan was created by conjugating the moderately-toxic drug, SN-38, site-specifically and at a high ratio of drug to antibody to a humanized antibody that targets the TROP-2 receptor expressed by many solid cancers. SN-38 is the active metabolite of irinotecan, which is used to treat certain solid cancers, particularly metastatic colorectal cancers, as a part of combination therapies, so its pharmacology and properties are well-known. Despite the late-stage setting, 1 patient in each of the colorectal and esophageal cancer groups had a partial response after receiving more than 2 doses of the ADC. For all 4 cancer types, the disease stabilization rate exceeded 50%.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use